Clarivate Plc (16A)
XHAN 
Summary
16A Chart
Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business
Clarivate NYSE: CLVT said it has reached an agreement to sell substantially all of its Life Sciences & Healthcare segment to Altaris, an investment firm focused on the healthcare industry, in a transaction valued at $600 million.
Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough
Clarivate delivered improved Q1 2026 results, with organic growth turning positive at 0.6% and margin expansion, but reported revenue still declined year over year. Segment trends stabilized, notably with Academia & Government and Life Sciences & Healthcare returning to growth, though IPPG remained a drag at -1.3% organic growth. AI-driven product enhancements and the Value Creation Plan could accelerate organic growth, but sustained improvement is needed before a re-rating is justified.
Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript
Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript
Clarivate Plc (16A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Clarivate Plc ever had a stock split?
Clarivate Plc Profile
| Software Industry | Information Technology Sector | Matitiahu Shem Tov CEO | XHAN Exchange | JE00BJJN4441 ISIN |
| GB Country | 12,000 Employees | 15 Mar 2018 Last Dividend | - Last Split | 29 Oct 2018 IPO Date |
Overview
Clarivate Plc operates as a distinguished information services provider with a broad geographical footprint spanning the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company offers its services under three main segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. Its mission is to support academic, corporate, and government agencies, along with public libraries and other professional services organizations, with critical data, insights, and services that span the spectrum of academic research, pharmaceutical development, and intellectual property management. Established in 1864 and rebranded from Clarivate Analytics Plc to Clarivate Plc in May 2020, it is headquartered in London, United Kingdom, signifying a legacy combined with a modern approach towards information services.
Products and Services
- Web of Science and InCites: A duo offering that enables the exploration and analysis of the academic research landscape, managing research information effectively.
- ProQuest One and Ebook Central: These platforms provide comprehensive content collections in a cost-effective manner to academic and governmental institutions, enhancing the availability of valuable resources.
- Alma and Polaris: Specialized in managing academic resources and services, these applications facilitate the connection between users and support various research publications through efficient management.
- Patent and Trademark Renewals: Focused on alleviating the workload for paralegals and admins, this service streamlines the process of patent and trademark protection and maintenance.
- CompuMark and Derwent: These services assist in making informed decisions regarding patent and trademark protection, minimizing risk and enhancing value creation through all stages of the innovation and brand lifecycle.
- IPFolio and Foundation IP: Offering a structured environment for the management and protection of global patent and trademark assets, these platforms cater to the nuanced needs of IP management.
- Cortellis Competitive Intelligence and Cortellis Drug Discovery Intelligence: Support the development of new drugs and medical devices from discovery to clinical trials, providing vital data and insights for the pharmaceutical industry.
- Cortellis Regulatory Intelligence and OFF-X: These tools monitor drug safety issues and ensure adherence to regulatory protocols, vital for the timely and safe development of pharmaceuticals.
- Real World Data and Optimize: Aimed at informing commercial launch strategies and setting pricing for optimal reimbursement, these offerings leverage real-world data to guide healthcare business decisions.
